Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders
January 27, 2023 09:00 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and fully integrated gene therapy company dedicated to challenging the...
Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A
December 12, 2022 12:00 ET
|
Spark Therapeutics, Inc.
Multi-year data, with up to five years of follow up, show sustained expression of FVIII in more than 90% of participants, in addition to improved annual bleeding and infusion ratesData shared during...
Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successor
February 23, 2022 10:29 ET
|
Spark Therapeutics, Inc.
Under Jeff Marrazzo’s leadership, Spark launched world’s first FDA-approved gene therapy for a genetic disease. He also spearheaded Spark’s $4.8 billion acquisition by Roche. Company’s...
Spark Therapeutics to Invest $575M in New 500k Square Foot State-of-the-Art Gene Therapy Innovation Center on Drexel’s University City Campus
December 17, 2021 08:00 ET
|
Spark Therapeutics, Inc.
Roche affirms its long-term commitment to Philadelphia as gene therapy center of excellence Spark signs 99-year ground lease of Drexel University’s property, to create a premier environment for...
Spark Therapeutics Updated SPK-8011 Data from Phase 1/2 Study Shows Multi-Year, Durable Factor VIII (FVIII) Expression that Significantly Reduced Bleeding in Hemophilia A Patients
November 17, 2021 17:01 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to...
Spark Therapeutics and CombiGene Enter into Exclusive, Global Licensing Agreement for Gene Therapy Candidate CG01
October 12, 2021 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to...
Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date
July 21, 2021 10:12 ET
|
Spark Therapeutics, Inc.
Factor VIII (FVIII) expression was sustained in 16 of 18 participants with up to 4 years of follow-up to the administration of SPK-8011 Across all dose cohorts, there was a 91.2% reduction in...
Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform
April 13, 2021 08:30 ET
|
Spark Therapeutics, Inc.
Collaboration combines Senti Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics’ investigational gene therapies...
Spark Therapeutics Further Strengthens Technical Expertise with Appointment of Cynthia Pussinen as Chief Technical Officer
February 25, 2021 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to...
Spark Therapeutics Announces Preliminary Data from Phase 1/2 Clinical Trial of SPK-8016 in Hemophilia A at EAHAD 2021 Virtual Congress
February 05, 2021 10:51 ET
|
Spark Therapeutics, Inc.
Preliminary data from four participants who received investigational SPK-8016 at a dose of 5X1011 vg/kg and have no history of FVIII inhibitors show no serious adverse events and stable and durable...